《丙型肝炎防治指南(2022年版)》解读：特殊人群抗病毒治疗

曾庆磊; 纪泛扑

doi:10.3969/j.issn.1001-5256.2023.07.008

《丙型肝炎防治指南(2022年版)》解读：特殊人群抗病毒治疗

DOI: 10.3969/j.issn.1001-5256.2023.07.008

曾庆磊¹,
纪泛扑^2, , ,

1.
郑州大学第一附属医院感染病科，郑州 450052
2.
西安交通大学第二附属医院感染病科，西安 710004

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：曾庆磊、纪泛扑共同提出写作思路、完成写作、相互校对和总体校对。

详细信息

通信作者:
纪泛扑，jifanpu1979@163.com(ORCID：0000-0002-1463-8035)

计量
- 文章访问数: 601
- HTML全文浏览量: 90
- PDF下载量: 193
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-15
- 录用日期: 2023-06-18
- 出版日期: 2023-07-20

Interpretation of guideline for the prevention and treatment of hepatitis C (2022 version): Antiviral therapy for special populations

Qinglei ZENG¹,
Fanpu JI^{2
, ,
,}

1.
Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
2.
Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China

More Information

Corresponding author: JI Fanpu, jifanpu1979@163.com(ORCID: 0000-0002-1463-8035)

摘要

摘要: 中华医学会肝病学分会和感染病学分会于2022年组织国内专家对丙型肝炎防治指南进行更新，新版指南从流行病学、人群的筛查与预防、实验室检测、诊断流程和治疗方案的简化、特殊人群抗病毒治疗等方面进行了更新。本文拟对新指南中未明确提及的特殊人群包括孕妇和肝细胞癌患者的治疗及尚需解决的问题进行解读，以供临床医生在实际工作中参考与借鉴。
- 丙型肝炎 /
- 治疗学 /
- 诊疗准则
Abstract: In 2022, Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association, organized domestic experts to update the guideline for the prevention and treatment of hepatitis C from the aspects of epidemiology, population screening and prevention, laboratory testing, simplification of diagnostic processes and treatment regimens, and antiviral therapy for special populations. This article aims to interpret the treatment of special populations not specifically mentioned in the new guideline, including pregnant women and patients with hepatocellular carcinoma, as well as other issues that need to be solved, in order to provide a reference for clinicians in practical work.
- Hepatitis C /
- Therapeutics /
- Practice Guideline

HTML全文

参考文献(21)

[1]	GOWER E, ESTES C, BLACH S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014, 61(1 Suppl): s45-s57. DOI: 10.1016/j.jhep.2014.07.027.
[2]	Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study[J]. Lancet Gastroenterol Hepatol, 2022, 7(5): 396-415. DOI: 10.1016/S2468-1253(21)00472-6.
[3]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C (2022 version)[J]. Chin J Clin Infect Dis, 2022, 15(6): 428-447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15(6) : 428-447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.
[4]	European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series☆[J]. J Hepatol, 2020, 73(5): 1170-1218. DOI: 10.1016/j.jhep.2020.08.018.
[5]	ZENG QL, ZHANG JY, ZHANG Z, et al. Sofosbuvir and ABT-450: terminator of hepatitis C virus?[J]. World J Gastroenterol, 2013, 19(21): 3199-3206. DOI: 10.3748/wjg.v19.i21.3199.
[6]	ZHU SS, ZENG QL, DONG Y, et al. Interferon-α plus ribavirin yields 98% sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C[J]. Hepatol Int, 2015, 9(4): 578-585. DOI: 10.1007/s12072-015-9671-8.
[7]	SPERA AM, ELDIN TK, TOSONE G, et al. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women?[J]. World J Hepatol, 2016, 8(12): 557-565. DOI: 10.4254/wjh.v8.i12.557.
[8]	ABDALLAH M, ALBORAIE M, ABDEL-RAZEK W, et al. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort[J]. Liver Int, 2021, 41(7): 1494-1497. DOI: 10.1111/liv.14913.
[9]	ZENG QL, YU ZJ, LV J, et al. Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study[J]. J Med Virol, 2022, 94(9): 4548-4553. DOI: 10.1002/jmv.27877.
[10]	BHATTACHARYA D, ARONSOHN A, PRICE J, et al. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection[J]. Clin Infect Dis, 2023. DOI: 10.1093/cid/ciad319.[Online ahead of print]
[11]	GAO X, JI FP. Diagnosis and treatment strategies of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antiviral drugs[J]. Chin J Hepatol, 2020, 28(10): 827-830. DOI: 10.3760/cma.j.cn501113-20200914-00516. 高旭, 纪泛扑. 直接抗病毒药物时代丙型肝炎病毒相关肝细胞癌的诊治对策[J]. 中华肝脏病杂志, 2020, 28 (10): 827-830. DOI: 10.3760/cma.j.cn501113-20200914-00516.
[12]	REIG M, CABIBBO G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)[J]. J Hepatol, 2021, 74(5): 1225-1233. DOI: 10.1016/j.jhep.2021.01.046.
[13]	MOCAN T, NENU I, CRǍCIUN R, et al. Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare?[J]. J Gastroenterol Hepatol, 2021, 36(6): 1518-1528. DOI: 10.1111/jgh.15376.
[14]	WAZIRY R, HAJARIZADEH B, GREBELY J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression[J]. J Hepatol, 2017, 67(6): 1204-1212. DOI: 10.1016/j.jhep.2017.07.025.
[15]	JI F, YEO YH, WEI MT, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis[J]. J Hepatol, 2019, 71(3): 473-485. DOI: 10.1016/j.jhep.2019.04.017.
[16]	PRENNER SB, VANWAGNER LB, FLAMM SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals[J]. J Hepatol, 2017, 66(6): 1173-1181. DOI: 10.1016/j.jhep.2017.01.020.
[17]	SINGAL AG, RICH NE, MEHTA N, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma[J]. Gastroenterology, 2019, 157(5): 1253-1263. e2. DOI: 10.1053/j.gastro.2019.07.040.
[18]	DANG H, YEO YH, YASUDA S, et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both East and West[J]. Hepatology, 2020, 71(6): 1910-1922. DOI: 10.1002/hep.30988.
[19]	JI F, LI T, NGUYEN MH. Improved survival and high sustained virologic response with DAA therapy in patients with HCV-related HCC: A call for expanded use[J]. J Gastroenterol Hepatol, 2021, 36(6): 1721-1722. DOI: 10.1111/jgh.15420.
[20]	KUDO M, FINN RS, QIN S, et al. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study[J]. J Hepatol, 2023, 78(1): 133-141. DOI: 10.1016/j.jhep.2022.09.006.
[21]	REN Z, QIN S, MENG Z, et al. A phase 2 study of camrelizumab for advanced hepatocellular carcinoma: Two-year outcomes and continued treatment beyond first RECIST-defined progression[J]. Liver Cancer, 2021, 10(5): 500-509. DOI: 10.1159/000516470.